{"url_path":"/sec/idya/8-k/2026-06-01/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1676725/0001193125-26-251399-index.html","accession_number":"0001193125-26-251399","cik":"0001676725","ticker":"IDYA","issuer_name":"IDEAYA Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1676725/0001193125-26-251399-index.html","primary_entity_key":"0001676725","primary_entity_name":"IDEAYA Biosciences, Inc."},"word_count":495,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\nNo.\n  \nDescription\n\n99.1\n  \n[ASCO Presentation, dated June 1, 2026.](d138848dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\nForward-Looking Statements\n\nCertain statements contained herein are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding: (i) the potential therapeutic benefit, safety, tolerability and clinical activity of darovasertib in combination with crizotinib; (ii) the potential significance and implications of data from the Phase 2/3 registrational OptimUM-02 trial; (iii) expectations regarding overall survival analyses and timing of interim data updates; (iv) the Company’s plans and expectations regarding regulatory submissions, including the timing and completion of the NDA submission under the FDA’s Real-Time Oncology Review program; (v) the potential for accelerated approval and/or full approval of darovasertib in combination with crizotinib in the United States and globally; and (vi) the Company’s strategy, business plans and objectives. Such forward-looking statements are based on the Company’s current expectations, estimates, assumptions, and beliefs regarding future events and are subject to substantial risks and uncertainties that could cause actual results, outcomes or events to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others: risks related to the discovery, development and regulatory approval of drug candidates; risks related to the timing, progress and results of clinical trials, including uncertainties regarding enrollment, safety, efficacy and durability of response; risks that clinical trial results may not be replicated in future studies or support regulatory approval; risks related to regulatory interactions, submissions and decisions, including the timing and outcome of NDA review processes; risks related to manufacturing and supply; risks related to competition and changes in the standard of care; the timing and success of commercialization efforts; the outcome of collaborations and licensing arrangements; the Company’s dependence on third parties; and risks related to the Company’s ability to obtain, maintain, protect and enforce intellectual property rights for its product candidates. All forward-looking statements are made as of the date hereof, and the Company undertakes no obligation to update any forward-looking statements to reflect new information, future events, or otherwise, except as required by law. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company’s Annual Report on Form 10-K dated February 17, 2026, the Company’s Quarterly Report on Form 10-Q dated May 5, 2026, and any subsequently filed current and periodic reports filed or furnished with the Securities and Exchange Commission.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nIDEAYA BIOSCIENCES, INC.\n\nDate: June 1, 2026\n \n\n \nBy:\n \n\n/s/ Yujiro Hata\n\n \n\n \n\n \nYujiro Hata\n\n \n\n \n\n \nPresident and Chief Executive Officer"}